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Placental ischemia and soluble 
fms-like tyrosine kinase 1: Cause 
or consequence of preeclampsia?
SA Karumanchi1,2 and FH Epstein1
Elevated circulating soluble fms-like tyrosine kinase 1 (sFLT-1) is 
associated with the development of the clinical signs and symptoms 
of preeclampsia. Placental ischemia has been suggested as one of the 
etiological factors that mediate increased sFLT-1 production in patients 
with preeclampsia, but definitive evidence for this hypothesis was 
lacking. Makris et al. demonstrate that inducing placental ischemia in 
primates is sufficient to induce sFLT-1 upregulation and the clinical 
signs and symptoms of preeclampsia.
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Although the etiology of preeclampsia is 
still unclear, its manifestations, including 
endothelial dysfunction, hypertension, 
and proteinuria, are thought to medi-
ated by high circulating concentrations 
of antiangiogenic proteins such as solu-
ble fms-like tyrosine kinase 1 (sFLT-1, or 
sVEGFR1).1,2 sFLT-1 induces endothe-
lial dysfunction by inhibiting vascular 
endothelial growth factor (VEGF) sign-
aling, particularly in endothelial cells that 
are fenestrated and that have constitutive 
expression of VEGF, such as those that 
reside in the glomerulus of the kidney 
(Figure 1). Th e evidence that sFLT-1 plays 
a causal role in mediating the clinical 
symptoms of preeclampsia is gradually 
accumulating. It includes the following: 
(1)     Patients with clinical disease have 
high circulating concentrations 
of sFLT-1.3–5 Levels of sFLT-1 are 
highest among those patients with 
the most severe forms of the disease, 
such as in preterm preeclampsia or 
in those whose infants are small for 
gestational age (SGA).5–7
(2)     Th e levels of sFLT-1 start rising at 
least 5–6 weeks before the onset of 
symptoms and reach a peak with the 
onset of the disease.7–10
(3)     Increased circulating levels of sFLT-
1 are associated with a fall in free 
VEGF and free placental growth 
factor (a related proangiogenic mol-
ecule) in patients with preeclamp-
sia.4,11,12
(4)     A fall in sFLT-1 levels following 
delivery of the placenta corre-
lates with improvement in clinical 
symptoms.4 Moreover, the spon-
taneous resolution of preeclamp-
sia symptoms in pregnant patients 
with parvovirus-induced hydrops 
aft er correction of fetal anemia and 
hydrops is associated temporally 
with a fall in circulating sFLT-1 con-
centrations.13
(5)    Th e endothelial dysfunction induced 
by preeclamptic serum can be 
reversed by removal of sFLT-114 
or by addition of excess VEGF in 
endothelial-cell culture studies.4
(6)    Elevating sFLT-1 levels in pregnant 
rats induces hypertension, proteinu-
ria, and glomerular endotheliosis, 
the hallmarks of preeclampsia.4
(7)    Anti-VEGF antibodies given to 
experimental animals lead to 
glomerular endothelial damage 
with proteinuria,15,16 as does genetic 
deletion of podocyte production of 
VEGF.17
(8)    Several risk factors for preeclamp-
sia can be explained by increases in 
sFLT-1 levels. These include mul-
tigestational pregnancies, high-
altitude pregnancies, trisomy 13, 
and nulliparity (Y Bdolah et al., J 
Soc Gynecol Investig 2006; 13: A670, 
abstr.).18–20 Furthermore, a decrease 
in circulating sFLT-1 levels among 
smokers may explain the decreased 
incidence of preeclampsia in this 
subgroup.6,21
(9)    Th e use of VEGF inhibitors in some 
cancer patients may not only induce 
hypertension and proteinuria but 
occasionally produce reversible 
posterior leukoencephalopathy — a 
syndrome characteristic of patients 
with eclampsia.22–24
(10)  Increased incidence of cardiovas-
cular diseases25 and relative paucity 
of solid cancers26 in patients with a 
history of preeclampsia may suggest 
that there may be a persistent anti-
angiogenic state in these patients.
The etiology of increased sFLT-1 in 
preeclampsia is still not known. Although 
the placenta appears to be the major 
source of circulating sFLT-1,4,27 other 
sources, such as activated mononuclear 
cells, may also contribute to the rise in 
circulating levels.28 Whereas the role of 
sFLT-1 in inducing the maternal syn-
drome is fairly well understood, its actions 
in the placenta are still not known. sFLT-1 
inhibits trophoblast migration and diff er-
entiation in vitro and therefore has been 
hypothesized to be responsible at least 
in part for the placental abnormalities 
noted in preeclampsia.14,29 It is interest-
ing that the maternal circulating levels of 
sFLT-1 rise toward the end of pregnancy, 
though not to the extent seen in preec-
lampsia.6,7,29,30 It is tempting to hypothe-
size that this ‘normal’ production of an 
antiangiogenic protein is nature’s way 
of slowing and reversing the exuberant 
placental angiogenesis that marks 
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mammalian pregnancy. However, in vivo 
evidence for this hypothesis is lacking. 
Given that sFLT-1 becomes elevated near 
the time of clinical disease (usually in the 
latter half of pregnancy), other factors that 
impair placentation early in pregnancy 
may induce placental ischemia/hypoxia 
that in turn leads to sFLT-1 upregulation. 
Indeed, sFLT-1 is upregulated in response 
to hypoxia in vitro.31
The article by Makris et al.32 (this 
issue) describes an artifi cial model of 
preeclampsia produced in nonhuman 
primates by decreasing the blood fl ow to 
the uteroplacental compartment. Th ese 
animals develop hypertension and pro-
teinuria that is very similar to the pic-
ture of placental ischemia produced 
in rodents.33 However, in contrast to 
rodents, in which evidence of glomeru-
lar endotheliosis has not been consist-
ently noted, these primates develop a 
renal lesion resembling the endothelio-
sis of human preeclampsia. Fetal growth 
restriction, a hallmark of preterm preec-
lampsia but not term preeclampsia, was 
not noted in this primate model. Very 
interestingly, the authors report tenfold-
increased circulating concentrations of 
sFLT-1 associated with the appearance 
of hypertension and proteinuria. Th ese 
data provide further evidence in favor 
of sFLT-1 as the mediator of the clini-
cal symptoms of preeclampsia. Further-
more, Makris et al.32 provide direct 
evidence that preeclampsia can be pro-
duced by placental ischemia. Although 
placental ischemia may not be respon-
sible for all cases of human preeclamp-
sia, the article by Makris et al.32 gives 
strong evidence that placental ischemia 
alone is suffi  cient to induce preeclamp-
sia and that the signs and symptoms of 
preeclampsia thus induced are mediated 
by sFLT-1.
Th is primate model of preeclampsia 
provides a wonderful opportunity for 
investigators to test novel therapeutic 
strategies against sFLT-1, such as VEGF, 
placental growth factor, or neutralizing 
antibodies designed to bind sFLT-1. It 
would be interesting to see whether this 
model of preeclampsia is also character-
ized by high circulating concentrations of 
soluble endoglin, a novel antiangiogenic 
substance that has been recently shown to 
synergize with sFLT-1 in the pathogenesis 
of preeclampsia (Figure 1).34
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Evidence mounts for a role of the 
kidney in lipoprotein(a) catabolism
JJ Albers1, ML Koschinsky2 and SM Marcovina1
Numerous studies have suggested a role of the kidney in lipoprotein(a) 
(Lp(a)) catabolism, but direct evidence is still lacking. Frischmann et al. 
demonstrate that the marked elevation of Lp(a) observed in hemodialysis 
patients results from a decrease in Lp(a) clearance rather than an increase 
in Lp(a) production, consistent with the notion that the kidney degrades 
Lp(a). More studies are needed to prove the biological relevance. 
Kidney International (2007) 71, 961–962. doi:10.1038/sj.ki.5002240
Lipoprotein(a) (Lp(a)) consists of a low-
density lipoprotein (LDL)-like particle 
containing one molecule of apolipopro-
tein B-100 (apoB-100) covalently linked 
by a sulfh ydryl bond to one molecule of 
apolipoprotein(a) (apo(a)). Th e carbohy-
drate-rich glycoprotein apo(a) is highly 
polymorphic and is formed by variable 
copies of the kringle 4 domain, one copy 
of a kringle 5 domain, and an inactive 
protease domain.
Lp(a) is almost exclusively derived from 
the liver. Frischmann and co-workers1 
(this issue) compared the in vivo turnover 
rates of both the apoB-100 component and 
the apo(a) component of Lp(a) by stable-
isotope technology in healthy controls and 
in hemodialysis patients. Th is work dem-
onstrated that the apoB-containing lipo-
proteins from which Lp(a) is assembled 
are almost exclusively a newly synthesized 
pool derived from the liver in both controls 
and hemodialysis patients whereas only a 
very small percentage of Lp(a) is assem-
bled from circulating LDL. Plasma levels of 
Lp(a) are highly variable; most of the varia-
tion is attributed to diff erences in the Lp(a) 
production rate controlled by the apo(a) 
gene locus. Considerable progress has 
been made in regard to our understanding 
of Lp(a) assembly and production, but little 
is known about the sites and mechanisms 
responsible for Lp(a) clearance (Figure 1).
Th ere is now a considerable amount of 
evidence supporting the concept that the 
kidney plays a significant role in Lp(a) 
clearance. First, Lp(a) plasma concentra-
tions are elevated in patients with impaired 
renal function,2 and the degree of Lp(a) 
elevation inversely correlates with the 
glomerular fi ltration rate.3 Interestingly, 
the majority of studies have suggested that 
the high-molecular weight forms of Lp(a) 
are selectively elevated in patients with 
impaired renal function. Second, after 
kidney transplantation in patients with 
impaired renal function, Lp(a) concentra-
tions generally decrease.4 Th ird, Kronen-
berg and co-workers5 reported that Lp(a) 
levels in the renal vein are lower than those 
in the ascending aorta, suggesting that 
Lp(a) is removed in the renal circulation. 
Fourth, Reblin and co-workers6 showed, in 
a heterologous rat model, that when Lp(a) 
is injected in rats, Lp(a) accumulates in the 
kidney tubules and apo(a) fragments are 
excreted in the urine. Fift h, patients with 
impaired renal function have decreased 
urinary apo(a) excretion.2 Frischmann and 
co-workers1 have extended these observa-
tions that support a role of the kidney in 
the clearance of Lp(a) by demonstrating 
that hemodialysis patients with impaired 
renal function have a decrease in Lp(a) 
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